eLife (Mar 2022)

Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer

  • Yixiao Zhang,
  • Lisha Sun,
  • Haonan Li,
  • Liping Ai,
  • Qingtian Ma,
  • Xinbo Qiao,
  • Jie Yang,
  • Hao Zhang,
  • Xunyan Ou,
  • Yining Wang,
  • Guanglei Chen,
  • Jinqi Xue,
  • Xudong Zhu,
  • Yu Zhao,
  • Yongliang Yang,
  • Caigang Liu

DOI
https://doi.org/10.7554/eLife.68481
Journal volume & issue
Vol. 11

Abstract

Read online

Background: Integrin family are known as key gears in focal adhesion for triple-negative breast cancer (TNBC) metastasis. However, the integrin independent factor TLN1 remains vague in TNBC. Methods: Bioinformatics analysis was performed based on TCGA database and Shengjing Hospital cohort. Western blot and RT-PCR were used to detect the expression of TLN1 and integrin pathway in cells. A small-molecule C67399 was screened for blocking TLN1 and integrin β1 through a novel computational screening approach by targeting the protein-protein binding interface. Drug pharmacodynamics were determined through xenograft assay. Results: Upregulation of TLN1 in TNBC samples correlates with metastasis and worse prognosis. Silencing TLN1 in TNBC cells significantly attenuated the migration of tumour cells through interfering the dynamic formation of focal adhesion with integrin β1, thus regulating FAK-AKT signal pathway and epithelial-mesenchymal transformation. Targeting the binding between TLN1 and integrin β1 by C67399 could repress metastasis of TNBC. Conclusions: TLN1 overexpression contributes to TNBC metastasis and C67399 targeting TLN1 may hold promise for TNBC treatment. Funding: This study was supported by grants from the National Natural Science Foundation of China (No. 81872159, 81902607, 81874301), Liaoning Colleges Innovative Talent Support Program (Name: Cancer Stem Cell Origin and Biological Behaviour), Outstanding Scientific Fund of Shengjing Hospital (201803), and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).

Keywords